Financial Markets

The first Humira biosimilar entered the European market in 2018. By 2020, the originator's market share had collapsed to roughly...

An analyst covering a mid-cap pharmaceutical company sits down with the latest quarterly filing and encounters a familiar problem. The...

There is a number that pharmaceutical executives discuss constantly in private and reference obliquely in public. It is not a...

The formula is elegant in its simplicity and far-reaching in its consequences. Medicare Part B reimburses most physician-administered drugs at...

List prices in pharmaceuticals are less prices than they are political objects—numbers that exist to be negotiated away, invoiced and...

Drug development traditionally rewards efficiency. Oral semaglutide quietly abandoned that principle. The injectable form of semaglutide achieves near‑complete systemic delivery....

Complex physiology produces complicated markets. The rapid expansion of peptide medicine has intersected with another long-standing domain of endocrine care:...

Modern pharmaceutical markets prefer certainty. Peptide biosignaling offers something closer to probability. As peptide therapies migrate from experimental laboratories into...

The metabolic‑drug boom was supposed to follow a predictable script. A new class of obesity medications would emerge, clinical results...

Few therapeutic categories illustrate the gap between pharmacology and practice as clearly as growth hormone peptides. From a distance, the...

Every autumn, a familiar conversation unfolds inside corporate boardrooms and human resources departments across the United States: how much more...

For most of modern pharmaceutical history, obesity drugs were an afterthought—periodically promising, frequently disappointing, and often politically radioactive. That equilibrium...